11月21日，华纳药厂跌6.60%，成交额2.03亿元。两融数据显示，当日华纳药厂获融资买入额3142.85万 元，融资偿还7880.02万元，融资净买入-4737.16万元。截至11月21日，华纳药厂融资融券余额合计3.10 亿元。 融资方面，华纳药厂当日融资买入3142.85万元。当前融资余额3.10亿元，占流通市值的5.19%，融资余 额超过近一年60%分位水平，处于较高位。 融券方面，华纳药厂11月21日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量0.00股，融券余额0.00元，超过近一年90%分位水平，处于高位。 资料显示，湖南华纳大药厂股份有限公司位于湖南省长沙市岳麓区麓天路28号C6-C7栋，成立日期2001 年4月30日，上市日期2021年7月13日，公司主营业务涉及化学原料药、化学药制剂和中药制剂的研发、 生产与销售。主营业务收入构成为：制剂产品73.19%，原料药及中间体25.22%，技术服务1.52%，植物 提取物及食品0.06%，其他0.01%。 截至9月30日，华纳药厂股东户数6416.00，较上期减少11.83%；人均流通股20467股， ...

11月21日，华纳药厂跌5%，截至发稿，报46.17元/股，成交7085.21万元，换手率1.15%，总市值60.63亿 元。华纳药厂股价已经连续5天下跌，区间累计跌幅7.07%。 资料显示，湖南华纳大药厂股份有限公司位于湖南省长沙市岳麓区麓天路28号C6-C7栋，成立日期2001 年4月30日，上市日期2021年7月13日，公司主营业务涉及化学原料药、化学药制剂和中药制剂的研发、 生产与销售。主营业务收入构成为：制剂产品73.19%，原料药及中间体25.22%，技术服务1.52%，植物 提取物及食品0.06%，其他0.01%。 截至发稿，李恭敏累计任职时间11年83天，现任基金资产总规模1.24亿元，任职期间最佳基金回报 28.83%， 任职期间最差基金回报-30.41%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 数据显示，招商基金旗下1只基金重仓华纳药厂。招商裕泰混合（016375）三季度持有股数7.79万股， 占基金净值比例为3.6%，位 ...

截至9月30日，华纳药厂股东户数6416.00，较上期减少11.83%；人均流通股20467股，较上期增加 13.42%。2025年1月-9月，华纳药厂实现营业收入10.86亿元，同比增长1.55%；归母净利润2.07亿元，同 比增长30.75%。 分红方面，华纳药厂A股上市后累计派现2.91亿元。近三年，累计派现2.25亿元。 11月14日，华纳药厂跌0.67%，成交额1.61亿元。两融数据显示，当日华纳药厂获融资买入额2459.82万 元，融资偿还2124.81万元，融资净买入335.01万元。截至11月14日，华纳药厂融资融券余额合计3.53亿 元。 融资方面，华纳药厂当日融资买入2459.82万元。当前融资余额3.53亿元，占流通市值的5.17%，融资余 额超过近一年70%分位水平，处于较高位。 融券方面，华纳药厂11月14日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量0.00股，融券余额0.00元，超过近一年90%分位水平，处于高位。 资料显示，湖南华纳大药厂股份有限公司位于湖南省长沙市岳麓区麓天路28号C6-C7栋，成立日期2001 年4月30日，上市日 ...

Core Viewpoint - Warner Pharmaceutical's stock increased by 5.06% to 61.43 CNY per share, with a total market capitalization of 8.067 billion CNY as of October 15 [1] Company Overview - Warner Pharmaceutical, established on April 30, 2001, is located in Changsha, Hunan Province, and was listed on July 13, 2021 [1] - The company's main business includes the research, production, and sales of chemical raw materials, chemical drug formulations, and traditional Chinese medicine formulations [1] - Revenue composition: 73.19% from formulations, 25.22% from raw materials and intermediates, 1.52% from technical services, 0.06% from plant extracts and food, and 0.01% from other sources [1] Shareholder Information - In the second quarter, Invesco Great Wall Fund's "Invesco Great Wall Research Selected Stocks A" (000688) entered the top ten circulating shareholders of Warner Pharmaceutical, holding 1.2882 million shares, which is 0.98% of the circulating shares [2] - The fund has achieved a year-to-date return of 45.98% and a one-year return of 54.96%, ranking 463 out of 4220 and 372 out of 3857 in its category, respectively [2] Fund Manager Profile - The fund manager of Invesco Great Wall Research Selected Stocks A is Jiang Shan, who has been in the position for 4 years and 65 days [3] - The total asset size of the fund is 10.811 billion CNY, with the best return during Jiang's tenure being 181.78% and the worst being -16.09% [3]

Core Insights - Warner Pharmaceutical's stock increased by 5.11% to 60.88 CNY per share, with a trading volume of 207 million CNY and a turnover rate of 2.68%, resulting in a total market capitalization of 7.995 billion CNY [1] Company Overview - Hunan Warner Pharmaceutical Co., Ltd. is located in Changsha, Hunan Province, and was established on April 30, 2001, with its listing date on July 13, 2021 [1] - The company's main business includes the research, production, and sales of chemical raw materials, chemical drug formulations, and traditional Chinese medicine formulations [1] - Revenue composition: Formulations account for 73.19%, raw materials and intermediates 25.22%, technical services 1.52%, plant extracts and food 0.06%, and others 0.01% [1] Shareholder Insights - Anxin Fund's Anxin Medical Health Stock A (010709) is among the top ten circulating shareholders of Warner Pharmaceutical, having increased its holdings by 504,400 shares in Q2, totaling 1,229,400 shares, which represents 0.94% of the circulating shares [2] - The estimated floating profit from this investment is approximately 3.639 million CNY [2] Fund Performance - Anxin Medical Health Stock A (010709) has a total asset size of 444 million CNY and has achieved a year-to-date return of 78.02%, ranking 57 out of 4,222 in its category [2] - Over the past year, the fund has returned 98.91%, ranking 578 out of 3,804, and since inception, it has achieved a return of 69.99% [2] Fund Manager Insights - The fund manager of Anxin Medical Health Stock A is Chi Chenshen, who has been in the position for 4 years and 251 days, with a total asset size of 946 million CNY [3] - The best fund return during his tenure is 72.35%, while the worst return is 68.37% [3] Fund Holdings - Anxin Medical Health Stock A (010709) has Warner Pharmaceutical as its sixth-largest holding, with 1,229,400 shares, accounting for 5.37% of the fund's net value [4] - The estimated floating profit from this position is also approximately 3.639 million CNY [4]

Group 1 - Warner Pharmaceutical's stock increased by 5.02%, reaching 53.93 CNY per share, with a trading volume of 199 million CNY and a turnover rate of 2.88%, resulting in a total market capitalization of 7.082 billion CNY [1] - The company, founded on April 30, 2001, and listed on July 13, 2021, is based in Changsha, Hunan Province, and specializes in the research, production, and sales of chemical raw materials, chemical drug formulations, and traditional Chinese medicine formulations [1] - The revenue composition of Warner Pharmaceutical includes 74.47% from formulations, 24.46% from raw materials and intermediates, 0.99% from other sources, and 0.08% from plant extracts and food [1] Group 2 - Jinxin Fund holds a significant position in Warner Pharmaceutical, with its Jin Xin Value Selected Mixed A Fund (005117) owning 41,000 shares, accounting for 4.25% of the fund's net value, making it the seventh-largest holding [2] - The Jin Xin Value Selected Mixed A Fund has achieved a year-to-date return of 70.97%, ranking 212 out of 8,254 in its category, and a one-year return of 112.38%, ranking 252 out of 8,037 [2] - The fund managers, Liu Shang, Zhao Haoran, and Tan Zhiwei, have varying tenures and performance records, with Zhao Haoran achieving the best return of 49.65% during his tenure [2]

Group 1 - The stock price of TianKang is reported at 34.36 yuan, down by 1.09 yuan, a decrease of 3.07% from the previous trading day [1] - During the trading session, the stock reached a high of 35.35 yuan and a low of 34.35 yuan, with a trading volume of 56,956 hands and a transaction amount of 198 million yuan [1] - TianKang's main business includes the research, production, and sales of pharmaceutical products, covering chemical drug formulations, traditional Chinese medicine formulations, and raw materials [1] Group 2 - The company is committed to providing high-quality pharmaceutical products and services to patients [1] - Public information indicates that a pension fund entered the top ten circulating shareholders of TianKang in the second quarter, with an additional holding value exceeding 100 million yuan [1] - Data shows that on August 26, TianKang experienced a net outflow of 35.95 million yuan in main funds, with a net outflow of 36.94 million yuan over the past five days [1]

Group 1 - As of August 21, 2025, Tianmu Pharmaceutical's stock price closed at 17.50 yuan, down 1.08 yuan from the previous trading day, with an opening price of 19.06 yuan and a trading range of 16.58% [1] - The company specializes in the research, production, and sales of traditional Chinese medicine, chemical drug formulations, and biological products, covering treatment areas such as cardiovascular, anti-tumor, and anti-infection [1] - On August 21, the stock experienced rapid fluctuations, with a rebound of over 2% within 5 minutes at 9:39 AM, and a decline of over 2% within 5 minutes at 9:35 AM [1] Group 2 - On August 21, the net outflow of main funds was 50.73 million yuan, accounting for 2.38% of the circulating market value, with a cumulative net outflow of 23.92 million yuan over the past five trading days, representing 1.12% of the circulating market value [1]

Company Overview - Tianmu Pharmaceutical's latest stock price is 15.91 yuan, an increase of 0.50 yuan from the previous trading day [1] - The stock reached a high of 16.18 yuan and a low of 15.35 yuan during the day, with a volatility of 5.39% [1] - The trading volume for the day was 76,644 hands, with a transaction amount of 120 million yuan [1] Business Operations - Tianmu Pharmaceutical is primarily engaged in the research, development, production, and sales of traditional Chinese medicine, chemical drug formulations, and biological products [1] - The company's product range covers multiple therapeutic areas, including cardiovascular, anti-tumor, and anti-infection treatments [1] Market Activity - On August 15, Tianmu Pharmaceutical experienced a rapid decline in the morning session, with a drop of over 2% within five minutes, followed by a gradual recovery [1] - The net outflow of main funds for the day was 4.4846 million yuan, while the cumulative net inflow of main funds over the past five trading days was 13.0701 million yuan [1]

Group 1 - The latest stock price of Xinguang Pharmaceutical is 20.05 yuan, an increase of 0.25 yuan from the previous trading day [1] - The stock opened at 18.86 yuan, reached a high of 20.28 yuan, and a low of 18.15 yuan, with an overall fluctuation of 10.76% throughout the day [1] - The trading volume was 260,458 hands, with a total transaction amount of 491 million yuan [1] Group 2 - Xinguang Pharmaceutical operates in the pharmaceutical manufacturing industry, specifically in the traditional Chinese medicine production sector [1] - The company is primarily engaged in the research, development, production, and sales of traditional Chinese medicine, chemical drug formulations, and raw materials [1] - Its product range covers multiple therapeutic areas, including cardiovascular, digestive, and respiratory systems [1] Group 3 - On August 4, the stock experienced a rapid rebound during the morning trading session, with a rise of over 2% within 5 minutes [1] - As of 9:37 AM, the stock price was reported at 18.95 yuan, with a transaction amount reaching 105 million yuan [1] - In terms of capital flow, there was a net outflow of 4.5732 million yuan from the main funds on that day, accounting for 0.2% of the circulating market value [1] - Over the past five trading days, the cumulative net inflow of main funds was 22.5547 million yuan, representing 0.99% of the circulating market value [1]